[SCHEDULE 13G/A] Maze Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin report joint beneficial ownership of 3,948,910 shares of Maze Therapeutics common stock, which the statement says represents 9.02% of the outstanding common shares. The holders report shared voting and shared dispositive power over those shares and no sole voting or dispositive power.

The ownership percentage is calculated from 43,797,166 shares outstanding per the issuer's public disclosures. The filing includes a certification that the shares were not acquired to change or influence control of the issuer and identifies Deep Track Capital, LP as the relevant entity for which David Kroin may be considered a control person.

Positive

• Material disclosure: Reporting persons jointly hold 3,948,910 shares representing 9.02% of Maze common stock
• Clear voting/dispositive structure: Holdings reported with shared voting and shared dispositive power, and no sole control

Negative

• None.

Insights

Financial Analyst

TL;DR: A passive 9.02% stake disclosed by Deep Track group is material in size but certified as not intended to influence control.

The reporting group holds 3,948,910 shares equal to 9.02% of Maze's common stock based on 43,797,166 shares outstanding. From a capital-structure perspective, a near-10% block is large enough to attract market attention and could affect liquidity for large trades, yet the Schedule 13G format and the certification indicate the holders characterize this position as passive rather than an active control effort. Investors should note the distinction between a 13G (passive) and a 13D (active), as it bears on potential governance engagement.

Corporate Governance Expert

TL;DR: Material shareholding disclosed jointly; the filing emphasizes shared power and a certification of no intent to influence control.

The filing shows shared voting and dispositive authority among the reporting persons and explicitly states the securities were not acquired to change control. Joint filing language and the identification of Deep Track Capital, LP as the relevant entity clarify reporting responsibility. For governance matters, the disclosure signals a significant passive stake without declared activist intent, which typically implies limited immediate governance impact absent future amendments or communications.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Maze Therapeutics Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

578784100

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 578784100

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,948,910.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,948,910.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,948,910.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.02 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 578784100

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,948,910.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,948,910.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,948,910.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.02 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 578784100

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,948,910.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,948,910.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,948,910.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.02 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Maze Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 171 Oyster Point Blvd., Suite 300, South San Francisco, CA 94080
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 578784100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,948,910
(b)	Percent of class: 9.02%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,948,910
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,948,910
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	08/14/2025

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	08/14/2025

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	08/14/2025

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of August 14, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined based on 43,797,166 Common Stock outstanding as of May 8, 2025, according to the issuer's 10-Q filed with the SEC on May 14, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin

FAQ

How many Maze Therapeutics (MAZE) shares does Deep Track group report owning?

The group reports beneficial ownership of 3,948,910 shares of Maze common stock.

What percentage of MAZE does the reported stake represent?

The reported stake represents 9.02% of Maze's outstanding common stock.

Does the filing indicate who has voting power over the shares?

Yes. The filing states shared voting power of 3,948,910 shares and no sole voting power for the reporting persons.

Is the position described as an attempt to influence control of MAZE?

No. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.

What outstanding share base was used to calculate the percentage?

The percentage is based on 43,797,166 shares outstanding per the issuer's public disclosure referenced in the filing.